DCTH insider filings
DELCATH SYSTEMS, INC. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-13. Screen DCTH transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 1 filing by 1 insider — 22,500 shares, $488,508 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 5.
- Largest priced transaction: sale of 20,570 shares @ $21.66 ($445,546) by Martell Bridget A, filed 2026-11-13.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Martell Bridget A — Director | 1 | — | 2 legs · 22,500 sh · $488,508 | 2 |
| Rosalind Advisors, Inc. — Director & SALAMON STEVEN A J — Director & Aharon Gil — Director | 1 | — | — | 3 |
Recent insider filings — DELCATH SYSTEMS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-13 | 4 | Martell Bridget A — Director | Option exercise (M): 22,500 @ $7.85 · Sale (S): 20,570 @ $21.66 · Sale (S): 1,930 @ $22.26 · Option exercise (M): 22,500 (derivative) @ $0 | EDGAR |
| 2026-10-14 | 4 | Rosalind Advisors, Inc. — Director SALAMON STEVEN A J — Director Aharon Gil — Director | Conversion (C): 3,627 @ $0 · Other (J): 27,502 @ $0 · Conversion (C): 36.27 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Aharon Gil — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Sylvester John Richard — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Martell Bridget A — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | SALAMON STEVEN A J — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | CZEREPAK ELIZABETH — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Pennell Sandra — Chief Financial Officer | Purchase (P): 5,533 @ $9.04 | EDGAR |
| 2026-03-03 | 4 | MICHEL GERARD J — CHIEF EXECUTIVE OFFICER, Director | Purchase (P): 11,200 @ $8.96 | EDGAR |
| 2026-02-18 | 4 | Rook Martha S. — CHIEF OPERATING OFFICER | Grant/award (A): 56,500 (derivative) @ $0 · Grant/award (A): 28,250 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Hoffman David L. — GEN'L COUNSEL, CCO & SECY | Grant/award (A): 56,500 (derivative) @ $0 · Grant/award (A): 28,250 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Muir Kevin — GM INTERVENTIONAL ONCOLOGY | Grant/award (A): 56,500 (derivative) @ $0 · Grant/award (A): 28,250 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Pennell Sandra — Chief Financial Officer | Grant/award (A): 56,500 (derivative) @ $0 · Grant/award (A): 28,250 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Vukovic Vojo — CHIEF MEDICAL OFFICER | Grant/award (A): 56,500 (derivative) @ $0 · Grant/award (A): 28,250 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | MICHEL GERARD J — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 195,000 (derivative) @ $0 · Grant/award (A): 97,500 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Sylvester John Richard — Director | Purchase (P): 4,386 @ $8.89 | EDGAR |
| 2025-11-13 | 4 | MICHEL GERARD J — CHIEF EXECUTIVE OFFICER, Director | Purchase (P): 11,500 @ $8.53 | EDGAR |
| 2025-06-13 | 4 | Vukovic Vojo — CHIEF MEDICAL OFFICER | Option exercise (M): 42,000 @ $4.78 · Option exercise (M): 42,000 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Aharon Gil — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Sylvester John Richard — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Martell Bridget A — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | SALAMON STEVEN A J — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | CZEREPAK ELIZABETH — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Aharon Gil — Director | Option exercise/expiry (X): 400,000 @ $10 | EDGAR |
| 2025-05-09 | 4 | SALAMON STEVEN A J — Director | Option exercise/expiry (X): 400,000 @ $10 | EDGAR |
| 2025-05-09 | 4 | Rosalind Advisors, Inc. — Director SALAMON STEVEN A J — Director Aharon Gil — Director | Option exercise/expiry (X): 400,000 @ $10 | EDGAR |
| 2025-02-07 | 4 | Rook Martha S. — CHIEF OPERATING OFFICER | Grant/award (A): 113,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Hoffman David L. — GEN'L COUNSEL, CCO & SECY | Grant/award (A): 113,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Muir Kevin — GM INTERVENTIONAL ONCOLOGY | Grant/award (A): 113,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Pennell Sandra — Chief Financial Officer | Grant/award (A): 113,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Vukovic Vojo — CHIEF MEDICAL OFFICER | Grant/award (A): 113,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | MICHEL GERARD J — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 390,000 (derivative) @ $0 | EDGAR |
| 2024-12-27 | 4 | SALAMON STEVEN A J — Director | Conversion (C): 250,000 @ $10 · Option exercise (M): 603,954 (derivative) @ $9.99 | EDGAR |
| 2024-12-26 | 4 | Aharon Gil — Director | Conversion (C): 250,000 @ $10 · Option exercise (M): 603,954 (derivative) @ $9.99 | EDGAR |
| 2024-12-26 | 4 | Rosalind Advisors, Inc. — Director SALAMON STEVEN A J — Director Aharon Gil — Director | Conversion (C): 250,000 @ $10 · Option exercise (M): 603,954 (derivative) @ $9.99 | EDGAR |
| 2024-11-01 | 4 | Aharon Gil — Director | Option exercise (M): 500 (derivative) @ $1,000 · Code (H): 0 (derivative) @ $0 | EDGAR |
| 2024-11-01 | 4 | SALAMON STEVEN A J — Director | Option exercise (M): 500 (derivative) @ $1,000 · Code (H): 0 (derivative) @ $0 | EDGAR |
| 2024-11-01 | 4 | Rosalind Advisors, Inc. — Director SALAMON STEVEN A J — Director Aharon Gil — Director | Option exercise (M): 500 (derivative) @ $1,000 · Code (H): 0 (derivative) @ $0 | EDGAR |
| 2024-10-23 | 4 | MICHEL GERARD J — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 16,666 @ $6 · Option exercise (M): 16,666 (derivative) @ $0.12 | EDGAR |
| 2024-05-28 | 4 | Aharon Gil — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Sylvester John Richard — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Martell Bridget A — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | SALAMON STEVEN A J — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | CZEREPAK ELIZABETH — Director | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | STOLL ROGER G PHD — Director | Disposition to issuer (D): 142 (derivative) @ $0 · Grant/award (A): 142 (derivative) @ $0 · Disposition to issuer (D): 40,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 · Disposition to issuer (D): 9,000 (derivative) @ $0 · Grant/award (A): 9,000 (derivative) @ $0 · +4 more | EDGAR |
| 2024-05-16 | 4/A | Aharon Gil — Director | Option exercise/expiry (X): 619,946 @ $0.01 · Conversion (C): 991,615 @ $0 | EDGAR |
| 2024-05-16 | 4 | SALAMON STEVEN A J — Director | Conversion (C): 991,615 @ $0 · Option exercise/expiry (X): 619,946 @ $6,199.46 | EDGAR |
| 2024-05-16 | 4/A | SALAMON STEVEN A J — Director | Option exercise/expiry (X): 619,946 @ $0.01 · Conversion (C): 991,615 @ $0 | EDGAR |
| 2024-05-16 | 4 | Rosalind Advisors, Inc. — Director SALAMON STEVEN A J — Director Aharon Gil — Director | Option exercise/expiry (X): 619,946 @ $6,199.46 · Conversion (C): 991,615 @ $0 | EDGAR |
| 2024-05-16 | 4/A | Rosalind Advisors, Inc. — Director SALAMON STEVEN A J — Director Aharon Gil — Director | Option exercise/expiry (X): 619,946 @ $0.01 · Conversion (C): 991,615 @ $0 | EDGAR |
Recent 8-K events — DELCATH SYSTEMS, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-14 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-20 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-11-04 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DCTH returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs